Immuron Limited · ASX:IMC

Immuron — Shareholder Meeting (November 2026)

11 slides from Immuron's shareholder meeting presentation, Nov 18, 2026

  1. Slide 1: ASX/NASDAQ Announcement: 2026 AGM CEO Address

    Slide 1: ASX/NASDAQ Announcement: 2026 AGM CEO Address

    For personal use only ASX/NASDAQ Announcement 18 November 2026 2026 Annual General Meeting - CEO Address Immuron Limited (ASX: IMC; NASDAQ: IMRN) attaches the CEO Address to be delivered by Chief Executive Officer, Steve Lydeamore, at today’s Annual General Meeting. - - - END - - - COMPANY CONTACT:

  2. Slide 2: Immuron Platform Technology and IMM-124E

    Slide 2: Immuron Platform Technology and IMM-124E

    returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller populat

  3. Slide 3: ProIBS and irritable bowel syndrome market

    Slide 3: ProIBS and irritable bowel syndrome market

    the plant Aloe barbadensis. Mill. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use –as ProIBS® is. The product is safe, and no interactio

  4. Slide 4: CEO Address, November 2026

    Slide 4: CEO Address, November 2026

    rsonal use only AGM PRESENTATION 18 NOVEMBER, 2026 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1

  5. Slide 5: Safe Harbor Statement

    Slide 5: Safe Harbor Statement

    SAFE HARBOR STATEMENT Cer tain st ate men ts mad e in th is p res en tatio n are fo r ward -lo o k in g statemen ts an d are b ase d on I mmu ro n’s c u r ren t ex pe c tat io n s, est imates an d pr oj ec ti o ns . Wo r ds su c h as “an ti c ip ates,” “exp ec ts ,” “ in ten d s,” “ pl an s,” “ b el

  6. Slide 6: Transitioning from development-led to commercially focused growth

    Slide 6: Transitioning from development-led to commercially focused growth

    Immuron is a company transitioning from development-led to commercially focused growth. Revenue trends remain positive, cash is sufficient to support operations, and management is seeking external partners for IMM-529 and Travelan® to unlock value while limiting funding risk. The principal valuation

  7. Slide 7: FY26 Financial Achievements

    Slide 7: FY26 Financial Achievements

    FY26 Financial Achievements rsonal use only United States Sales Global Sales Australian Sales Revenue Revenue Revenue $1.8m $7.7m $5.8m Up 7% Up 6% Up 10% Up 13% in $USD Gross Profit Margin Net Profit Cash 64.5% $(3.8)m $9.0m 0.9% $1.4m $6.2m2 decline1 improvement improvement 1. Gross Profit Margin

  8. Slide 8: FY26 Clinical Achievements and Operational Highlights

    Slide 8: FY26 Clinical Achievements and Operational Highlights

    FY26 Clinical Achievements and Operational Highlights rsonal use only New U.S. FDA approval Travelan® Department of IMM-529 n=851 trial Defense IND completed subaward Strategic reset Engaged Pullan New product launch aimed at Consulting to in Australia profitability and support partnering A yellow c

  9. Slide 9: Continued strong sales growth

    Slide 9: Continued strong sales growth

    Continued strong sales growth Global Global Year to Date Jul - Sep Oct - Dec Jan - Mar Apr - Jun rsonal use only + FY27 YTD October AUD$3.0 million up 10% on prior year FY25 $ 1.5 $ 2.5 $ 1.3 $ 2.0 FY26 $ 2.0 $ 2.2 $ 1.5 $ 2.0 FY27 $ 2.2 Australia + FY27 YTD October AUD$2.5 million up 16% on prior y

  10. Slide 10: FY27 Outlook

    Slide 10: FY27 Outlook

    FY27 Outlook rsonal use only Portfolio expansion Sales expansion Continued Travelan® • Planned UK launch • Evaluating additional in- Exploring partnerships to sales growth licensing opportunities • expand sales channels in • Developing new products the United States Continued improvement Strategic i

  11. Slide 11: Contact Information

    Slide 11: Contact Information

    rsonal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 IMMURON INVESTOR HUB COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH

Source: ASX announcement, Nov 18, 2026

More decks from Immuron Limited

All 112 Immuron decks